Government Push for Generic Drugs Finds Digital Ally in New Healthcare Portal
India's healthcare landscape is undergoing a significant transformation, led by national initiatives…
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner’s National Priority Voucher Pilot Program
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.…
Medkart Champions Generic Drug Quality Amid Rising Consumer Concerns
With growing scrutiny around the quality and reliability of generic medicines in…
Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases
Hinge Bio to receive $10 million upfront and is eligible to receive…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
September 03, 2025 21:47 ET Â | Source: Mesoblast Limited NEW YORK, Sept.…
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 02, 2025 21:33 ET Â | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:…
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:…
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules…